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ABSTRACT   
Background & Aims: Pre-clinical studies have shown aspirin to have anti-cancer 
properties and epidemiologic studies have associated aspirin use with longer survival 
times of patients with cancer. We studied 2 large cohorts to determine the association 
between aspirin use and cancer-specific mortality in patients with esophageal or 
gastric cancer. 
 
Methods: We performed a population-based study using cohorts of patients newly 
diagnosed with esophageal or gastric cancer, identified from cancer registries in 
England from 1998 through 2012 and the Scottish Cancer Registry from 2009 through 
2012. Low-dose aspirin prescriptions were identified from linkages to the United 
Kingdom Clinical Research Practice Datalink in England and the Prescribing 
Information System in Scotland. Deaths were identified from linkage to national 
mortality records, with follow up until September 2015 in England and January 2015 
in Scotland. Time-dependent Cox regression models were used to calculate hazard 
ratios (HR) and 95% CIs for cancer-specific mortality by low-dose aspirin use after 
adjusting for potential confounders. Meta-analysis was used to pool results across the 
two cohorts.   
 
Results: The combined English and Scottish cohorts contained 4654 esophageal 
cancer and 3833 gastric cancer patients including 3240 and 2392 cancer-specific 
deaths, respectively. The proportions surviving 1 year, based upon cancer-specific 
mortality, were similar in aspirin users vs non-users after diagnosis with esophageal 
cancer (48% vs 50% in England and 49% vs 46% in Scotland, respectively) or gastric 
cancer (58% vs 57% in England and 59% vs 55% in Scotland, respectively). There 
was no association between post-diagnosis use of low-dose aspirin and cancer-
specific mortality among patients with esophageal cancer (pooled adjusted HR, 0.98; 
95% CI, 0.89–1.09) or gastric cancer (pooled adjusted HR, 0.96, 95% CI, 0.85–1.08). 
Long-term aspirin use was not associated with cancer-specific mortality after 
diagnosis of esophageal cancer (pooled adjusted HR, 1.03; 95% CI, 0.85–1.25) or 
gastric cancer (pooled adjusted HR, 1.06; 95% CI, 0.85–1.32). 
 
Conclusions: In analyses of 2 large independent cohorts in the United Kingdom, low-
dose aspirin usage was not associated with increased survival of patients diagnosed 
with esophageal or gastric cancer. 
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Introduction 
 
Gastric and esophageal cancer are the third and eighth most common cancers 
worldwide, comprising 6.8% and 3.2% of total cancer incidence, respectively.1 These 
cancers have poor prognosis (with 5 year survival rates of gastric cancer of 29% and 
esophageal cancer of 20%),2 highlighting the need for additional treatment options. 
 
Aspirin is used as an analgesic at high doses, and as an anti-platelet to prevent 
cardiovascular disease at low-doses (usually around 75mg).3 Platelets play an 
important role in cancer growth and metastasis4-6 and aspirin has been shown to 
prevent experimentally induced metastases in mice.7 In humans, long term follow-up 
of randomised controlled trials of aspirin to prevent vascular events, have shown a 
50% reduction in cancer-specific death in esophageal and gastric cancer patients on 
aspirin,8 and a 60% reduction in the risk of metastases in non-colorectal 
gastrointestinal cancer patients on aspirin.9 These protective effects were observed 
regardless of aspirin dose but were only observed for adenocarcinomas.8;9 However, 
as these patients were taking aspirin prior to esophageal or gastric cancer diagnosis it 
remains unclear whether low-dose aspirin use after cancer diagnosis, a time point 
more relevant for clinical intervention, confers any benefit.  Furthermore, a more 
recent meta-analysis by the United States Preventive Services Task Force concluded 
that the effect of aspirin on cancer mortality was not clearly established.10 
 
Unfortunately, there have not been any epidemiological studies that have investigated 
the association between low-dose aspirin use after diagnosis of gastric or esophageal 
cancer and cancer-specific mortality. Three independent studies11-13 have reported 
marked protective effects of aspirin on all-cause mortality in gastric and esophageal 
cancer patients, but these associations could reflect non-cancer mortality. Furthermore, 
in two studies these associations were restricted to subgroups of esophageal cancer 
patients12 and esophageal squamous cell carcinoma patients,13 and in the third study,11 
the associations were attenuated when methods to reduce immortal time bias were 
employed. Further evidence on the impact of low-dose aspirin use in patients with 
esophageal or gastric cancer is required to inform the decision to start trials, and 
inform the conduct of ongoing trials.14  
 
Using two independent population-based datasets, we investigated the association 
between low-dose aspirin use and cancer-specific mortality in patients with 
esophageal or gastric cancer. 
Materials & methods 
 
Data sources 
England: The English data were based upon the UK Clinical Practice Research 
Datalink (CPRD), linked with the Office for National Statistics (ONS) and National 
Cancer Data Repository (NCDR). The NCDR contains data on all patients identified 
in all English cancer registries, including date and site of primary cancer diagnosis, 
tumor prognostic features (e.g. stage, grade, morphology) and treatment data. The 
CPRD is the largest computerized database of its kind in the world.  CPRD 
encompasses approximately 6% of the UK population and is broadly representative in 
terms of age, sex, ethnicity and body mass index (BMI).15 The CPRD contains 
information including patients’ diagnoses, demographics, medication prescriptions 
and comorbidities. The ONS death data for the UK contains information on the causes 
and dates of death. Linkages of the databases were conducted using the NHS number, 
date of birth, gender and postcode of each patient. As linkage involved the English 
NCDR, only patients registered in English GP practices were included in this study. 
Ethical approval for research using CPRD data has been obtained from a multicentre 
research ethics committee. The study protocol was approved by The Independent 
Scientific Advisory Committee for Medicines and Healthcare products Regulatory 
Agency Database Research (protocol number: 15_096RMn3) and was made available 
to reviewers.  
 
Scotland: The Scotland data utilised linkages between national datasets including the 
Scottish Cancer Registry (SMR06), the Prescribing Information System, the General / 
Acute Inpatient and Day Case dataset (SMR01), the Outpatient Attendance dataset 
(SMR00) and the National Records of Scotland Death Records, covering the entire 
population of Scotland. Created in 1958, the Scottish Cancer Registry captures 
information on all cancers occurring in Scotland, including date and site of primary 
cancer diagnosis, grade and treatment data. The Prescribing Information System holds 
records regarding all medicines dispensed in the community for the entire population 
of Scotland. The General / Acute Inpatient and Day Case dataset contains information 
on hospital diagnoses and operations, and the Outpatient Attendance dataset contains 
diagnoses and medical procedures from new and follow up appointments at outpatient 
clinics. The National Records of Scotland Death Records contain date and cause of 
death. Linkages between data sources were conducted using the Community Health 
Index number (a unique number to individuals in Scotland). The study was approved 
by the Privacy Advisory Committee of the National Health Service (NHS) National 
Services Scotland. 
 
Study design 
A cohort of individuals newly diagnosed with esophageal or gastric cancer (ICD 
codes C15 to C16, respectively) in England between 1998 and 2012, and in Scotland 
between 2009 and 2012 was identified from cancer registries. Patients with previous 
cancer diagnosis apart from non-melanoma skin cancer and in-situ tumors, were 
excluded from the cohort. Esophageal and gastric cancer-specific and all-cause deaths 
were identified from ONS records in England (available up to September 2015) and 
National Records of Scotland Death Records in Scotland (available up to January 
2015). Esophageal and gastric cancer-specific deaths were defined as those with 
underlying cause of death ICD codes C15, C16 or C26 (‘other and ill-defined 
digestive organs’ included as it seems unlikely that patients diagnosed with gastric or 
esophageal cancer would die from an unrelated digestive organ cancer).  In analyses 
of esophageal and gastric cancer-specific mortality, patients were censored at the time 
of death from other causes or end of follow-up.  Patients who died within the first six 
months after diagnosis of esophageal or gastric cancer were excluded from the 
analysis as it is unlikely post-diagnosis low-dose aspirin medication use would impact 
their prognosis. Thus, the accrual of person years at risk began six months after 
esophageal or gastric cancer diagnosis. Patients were followed up to the end of 
registration with the general practice, last date of data collection from general practice, 
date of death or end of ONS follow-up in England (30th September 2015) or the date 
they left Scotland or end of follow up in Scotland (1st January 2015).   
 
Exposure 
Low-dose aspirin (75 mg) use was identified from prescriptions within England from 
the CPRD and dispensed medications within Scotland from the Prescribing 
Information System. A quantity of 28 tablets was assumed for the less than 2% of 
prescriptions for which quantity was assumed incorrect (if less than seven or greater 
than 365), as this is the most common number of tablets in a prescription. One tablet 
of low-dose aspirin daily was assumed to be taken daily, as this has been designated 
to be the defined daily dose (DDD), by the World Health Organisation 
classification.16 High dose aspirin comprised less than 2% of total aspirin 
prescriptions, during the exposure period in England and Scotland, and was ignored in 
all analyses. 
 
Confounders 
Data on histology (including esophageal adenocarcinoma and squamous cell 
carcinoma), grade and treatment (radiotherapy, chemotherapy or surgery) within six 
months of diagnosis were retrieved from cancer registries in England (from NCDR) 
and the Scottish Cancer Registry. The following comorbidities	were	identified:	acute 
myocardial infarction, congestive heart disease, peripheral vascular disease, 
cerebrovascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes and 
renal disease. In England these comorbidities were identified from GP records before 
cancer diagnosis (based upon an average of 7.7 years of available records using a 
previously developed Read code list17). In Scotland these comorbidities were 
identified from hospital inpatient and outpatient clinic data available from 1999 (using 
a previously developed ICD code list18). Statin use was determined from medication 
data as described above. Deprivation level was determined from postcode of 
residence in England using the English Index of Multiple Deprivation, and in 
Scotland based upon postcode of residence using the 2009 Scottish Index of Multiple 
Deprivation.19 Smoking status (categorised as current, ex or never) and BMI were 
available from GP diagnosis codes prior to cancer diagnosis within the CPRD cohort; 
records older than 10 years were discarded. 
 
Statistical analysis 
Time-varying Cox regression models were used to calculate hazard ratios (HRs) and 
95% confidence intervals (95% CI) for cancer-specific mortality comparing aspirin 
users to non-users in esophageal and gastric cancer sites. In the main analysis low-
dose aspirin use from the date of diagnosis was considered a time varying covariate20 
with patients classified as non-users until 6 months after their first prescription at 
which point they became users until the end of follow-up. Using such a lag is 
recommended,21 as low-dose aspirin is unlikely to have an immediate effect on cancer 
progression. A diagram illustrating this design is shown in Supplementary Figure 1. 
The main model included the following variables: sex, age, year of diagnosis, 
deprivation (defined above, in fifths), cancer treatment within 6 months (using 
separate variables for radiotherapy, chemotherapy and surgery), comorbidities prior to 
diagnosis (using separate variables for acute myocardial infarction, congestive heart 
disease, peripheral vascular disease, cerebrovascular accident, pulmonary disease, 
peptic ulcer, liver disease, diabetes and renal disease) and statin and aspirin use (as 
time varying covariates, as defined above).  
 
Exposure-response analyses for duration of aspirin use were undertaken using a time-
varying covariate with patients deemed non-users until 6 months after their first 
prescription, a short term user between 6 months after their first prescription and 6 
months after their 365th tablet and a long term user after this time. Similar analyses 
were also conducted for different total amounts of low-dose aspirin use (182, 365, 548 
and 730 tablets). Tests for trend were calculated, within the regression models using 
Wald tests, based upon the estimated HR per category increase of aspirin use.  
Separate analyses were conducted within esophageal cancer cases by histology 
(adenocarcinoma and squamous cell carcinoma) and for adenocarcinoma in gastric 
cancer patients. Summary HRs and standard errors from England and Scotland were 
combined using fixed effects models to calculate pooled HRs.22 The probabilities of 
survival at 1 year after the start of follow-up was estimated in aspirin users and non-
users, based upon cancer-specific mortality in Kaplan-Meier curves plotted using the 
Simon and Makuch method to account for aspirin as a time varying covariate.23 All 
analyses were conducted using STATA 14 (StataCorp, College Station, TX, USA) 
statistical analysis software. 
 
Sensitivity analyses were conducted with a lag of zero years (in which the accrual of 
person years at risk began at diagnosis, and all deaths after diagnosis were included), 
a lag of 3 months (in which the accrual of person years at risk began at 3 months, and 
deaths in the first 3 months were excluded) and a lag of 1 year (in which the accrual 
of person years at risk began from 1 year after diagnosis, and deaths in the first year 
after diagnosis were excluded), see Supplementary Figure 1 for an illustration.  Two 
simplified analyses, which control for immortal time bias without using time-varying 
covariates,20 were conducted. First, aspirin exposure was based on any use in the year 
prior to diagnosis (in which the accrual of person years at risk began at diagnosis, and 
all deaths after diagnosis were included). Second, aspirin exposure was based on any 
use during the six months after diagnosis and the accrual of person years at risk began 
six months after diagnosis. Additional analyses were conducted comparing aspirin 
users with non-users after restricting each cohort to patients who did not use aspirin in 
the year prior to cancer diagnosis, and conversely those who were aspirin users prior 
to cancer diagnosis. Further analyses were also conducted comparing aspirin users 
with non-users after diagnosis adjusting for aspirin use in the year prior to diagnosis 
and comparing aspirin users with non-users after diagnosis stratifying by statin use 
during that time period. A separate analysis was also conducted additionally adjusting 
for tumor grade as well as an analysis restricted to patients treated with surgery, a 
more homogeneous cohort of lower stage patients. Analyses were repeated for all-
cause mortality outcomes. 
 
Further adjustments were possible in the English data only, in which cancer stage, 
smoking and BMI were available. We performed additional sensitivity analysis 
adjusting for tumor prognostic features (stage, grade) and patient lifestyle factors 
(smoking, alcohol consumption, obesity) using complete-case and multiple 
imputation with chained equations (MICE). The MICE imputation used ordered logit 
models with age, deprivation, death indicator and the baseline hazard function as 
covariates.24 Briefly, MICE is a simulation-based approach for handling missing data 
which leads to valid statistical inferences under certain circumstances.25  
 
For comparison with a previous study,12;26 a start/stop time-varying covariate analysis 
was conducted, basically investigating current aspirin use, in which patients became 
aspirin users upon the date of each aspirin prescription, and remained aspirin users for 
the duration of the prescription at which point they became aspirin non-users. These 
analyses were conducted with no lag, a 6 month lag (accrual of person years at risk 
starts at 6 months after diagnosis and the dates of aspirin prescriptions were moved 
forward 6 months) and a 1 year lag (accrual of person years at risk starts at 1 years 
and the date of aspirin prescriptions were moved forward 1 year) as described above	
and were adjusted for the confounders mentioned previously. Supplementary Figure 1 
contains diagrams illustrating these designs.    
 
A separate sensitivity analysis was conducted to investigate the association between 
cancer-specific mortality and consistent aspirin use. A nested case-control design was 
used in which cases who died due to esophageal or gastric cancer were matched on 
age (in 5 year intervals), year of cancer diagnosis (in 1 year intervals), gender and site 
(esophageal or gastric cancer) to up to five esophageal or gastric cancer risk-set 
controls who lived at least as long after their cancer diagnosis. The exposure period 
was from cancer diagnosis until 6 months prior to cancer-specific death in cases and 
for a period of identical duration from diagnosis in matched controls. Patients who 
died within 6 months of diagnosis were excluded. The number of aspirin tablets per 
day in the exposure period was determined and patients with greater than 0.8 (i.e. 
using over 80% of the time) were considered consistent aspirin users. Conditional 
logistic regression was then used to calculate odds ratios (ORs), and 95% CIs, for the 
association between consistent aspirin use and cancer-specific mortality, adjusting for 
treatment, deprivation, comorbidities and statin use. 
 
 
Results 
 
Patient cohorts 
In the English cohort there were 11,044 gastroesophageal cancer patients. After 
exclusion criteria were applied, 2,733 esophageal cancer and 2,391 gastric cancer 
patients remained for analysis (Figure 1). The median follow up in England was 1.3 
(minimum=0.5, maximum=17.2) years and 1.5 (minimum=0.5 years, 
maximum=17.2) years for esophageal and gastric cancer, respectively. There were 
1,867 and 1,478 esophageal and gastric cancer-specific deaths in the English cohort, 
respectively. The Scottish cohort contained 1,921 esophageal and 1,442 gastric cancer 
patients (Figure 1). Mean follow up in this cohort was 1.3 years (minimum=0.5 years, 
maximum=6 years) for esophageal cancer patients and 1.6 years (minimum=0.5 years, 
maximum=6 years) for gastric cancer patients. There were 1,373 esophageal and 914 
gastric cancer-specific deaths in the Scottish cohort. 
 
Patient Characteristics 
Patient characteristics by aspirin use are shown for esophageal and gastric cancer 
patients in Tables 1 and 2, respectively. For both esophageal and gastric cancer 
cohorts, aspirin users, compared with non-users, were more likely to be male, older, 
have a history of comorbidities and use statins. Aspirin users in the gastric cancer 
cohort were slightly more likely to have surgery and radiotherapy, but less likely to 
have chemotherapy and higher grade tumors than non-users. Aspirin users in the 
esophageal cancer cohort were also more likely to undergo radiotherapy, and less 
likely to have chemotherapy, however the rates of surgery were similar when 
compared to non-users. 
 
Association between aspirin use after diagnosis and survival 
In esophageal cancer patients, the proportion surviving 1 year from the start of 
follow-up, based upon cancer-specific mortality, in aspirin users and non-users was 
49% and 46% in Scotland and 48% and 50% in England, respectively. Similarly in 
gastric cancer patients, the proportion surviving 1 year in aspirin users versus non-
users was 59% and 55% in Scotland and 58% versus 57% in England, respectively. 
 
In esophageal and gastric cancer patients, there was little evidence of a reduction in 
cancer-specific mortality with any aspirin use compared with non-use before or after 
adjustment for confounders (pooled adjusted HR 0.98, 95% CI 0.89, 1.09 and 
adjusted HR 0.96, 95% CI 0.85, 1.08, respectively) (Table 3). These associations were 
similar in the Scottish and English cohorts. There was little evidence of a dose-
response relationship; in esophageal and gastric cancer patients using more than 730 
aspirin tablets the pooled adjusted HRs were 1.25, 95% CI 0.91, 1.71 and 1.12 95% 
CI 0.77, 1.64, respectively. Further analysis by histological subtype revealed no 
evidence of association in esophageal adenocarcinoma patients (pooled adjusted HR 
1.05, 95% CI 0.93, 1.19), esophageal squamous cell carcinoma patients (pooled 
adjusted HR 0.89, 95% CI 0.74, 1.07) or gastric adenocarcinoma patients (pooled 
adjusted HR 0.92, 95% CI 0.81, 1.04), see Table 3. 
 
Sensitivity analyses 
Table 4 shows sensitivity analyses.  In the majority of sensitivity analyses, the 
conclusions were little altered. In unlagged analysis for esophageal and gastric cancer, 
there was a slight reduction in cancer-specific mortality in aspirin users compared 
with non-users (adjusted HR 0.87, 95% CI 0.81, 0.93 and adjusted HR 0.84, 95% CI 
0.78, 0.92) but this was not apparent when a 3 month lag was used (adjusted HR 0.94, 
95% CI 0.86, 1.02 and adjusted HR 0.93, 95% CI 0.84, 1.02) or when 6 or 12 month 
lags were used. Of particular note the associations for esophageal and gastric cancer 
were similar after additional adjustment for grade (pooled adjusted HR 1.01, 95% CI 
0.90, 1.13 and adjusted HR 0.99, 95% CI 0.86, 1.13, respectively), stage and grade 
(adjusted HR 0.88, 95% CI 0.61, 1.27 and adjusted HR 1.25, 95% CI 0.71, 2.20, 
respectively), and smoking and BMI (adjusted HR 1.06, 95% CI 0.91, 1.24, adjusted 
HR 0.89, 95% CI 0.75, 1.05, respectively) in the English dataset. There was also little 
association when restricting the analysis to patients who underwent surgery (pooled 
adjusted HR 0.85, 95% CI 0.68, 1.05 and adjusted HR 1.00, 95% CI 0.82, 1.22, 
respectively) Also, there was no association between consistent aspirin use and 
esophageal or gastric cancer-specific mortality (pooled adjusted OR 0.92, 95% CI 
0.79, 1.06 and adjusted OR 0.94, 95% CI 0.78, 1.13, respectively). For comparison 
with a previous study,12;26  in separate start/stop time-varying covariate analyses, there 
was a marked protective effect of aspirin when no lag was applied (in esophageal and 
gastric cancer patients pooled adjusted HR 0.44, 95% CI 0.39, 0.49, and adjusted HR 
0.46, 95% CI 0.41, 0.53, respectively), a slight protective effect when a 6 month lag 
was applied (pooled adjusted HR 0.87, 95% CI 0.77, 0.97, and adjusted HR 0.81, 
95% CI 0.70, 0.94, respectively) and little evidence of association when a 12 month 
lag was applied (pooled adjusted HR 0.90, 95% CI 0.77, 1.06, and adjusted HR 0.99, 
95% CI 0.82, 1.18, respectively). 
 
Also, there was little association between aspirin use in the year preceding esophageal 
or gastric cancer diagnosis and mortality, compared with non-users (pooled adjusted 
HR 0.94, 95% CI 0.86, 1.02 and adjusted HR 0.95, 95% CI 0.88, 1.02, respectively).  
 
Discussion 
 
In two large independent population-based cohorts of esophageal and gastric cancer 
patients we did not find any evidence that low-dose aspirin use reduced the risk of 
cancer-specific or all-cause mortality. 
 
To date there have not been any previous studies investigating the impact of aspirin 
use on cancer-specific mortality in esophageal or gastric cancer patients. Only one 
observational study has investigated aspirin after diagnosis and all-cause mortality in 
gastric cancer patients, whilst three have investigated this association in esophageal 
cancer patients. A cohort study conducted in the Netherlands did not observe a 
statistically significant association (adjusted HR 0.87, 95% CI 0.47, 1.61) between 
current aspirin use after diagnosis and mortality in 750 gastric cancer patients12 but 
did report a marked reduction in mortality in 560 esophageal cancer patients (adjusted 
HR 0.42, 95% CI 0.30, 0.57).26 However it is possible that their analysis, which was 
of current aspirin use (using a start/stop time-varying covariate), could have led to 
reverse causation. Specifically, current aspirin users became aspirin non-users once 
their prescription was complete, therefore if medications were withdrawn from 
individuals who become terminally ill (as has been observed at other cancer sites27) 
then aspirin could artificially appear protective. Consistent with this bias, when we 
fitted models of current aspirin use (using a start/stop time-varying covariate) we 
observed similar marked protective effects, which seem implausible, and which were 
entirely attenuated once a year lag was used. In our main analysis we used a lag and 
once an individual became an aspirin user they remained an aspirin user, as seen in 
similar studies,28;29 which reduces this potential bias.  
 
A study based upon 2392 esophageal cancer patients from Scotland also observed a 
protective association for all-cause mortality in aspirin users after diagnosis (adjusted 
HR 0.54 95% CI 0.45, 0.64).11 However, this protective association was attenuated in 
additional nested case-control analyses conducted to reduce immortal time bias, (OR 
0.75, 95% CI 0.43, 1.31). Finally, a Chinese study of 1598 esophageal cancer patients 
observed a slight but significant reduction in 5 year mortality in low-dose aspirin 
users compared with non-users (relative risk 0.81).13 However this study did not 
contain any dose response analyses, did not adjust for comorbidities and was 
conducted in a very specific cancer subset (undergoing resection for esophageal 
squamous cell carcinoma or gastric cardia adenocarcinoma). Our findings are similar 
to a recent US study which investigated aspirin use prior to esophageal cancer in 130 
esophageal cancer patients, which found no association between medication use and 
cancer-specific mortality (HR 1.07 95% CI 0.52, 2.21),30 however their study did not 
investigate aspirin use after diagnosis and had limited power.  
 
Long term follow-up of randomised controlled trials of aspirin, designed with the 
primary aim to prevent vascular events, have detected reductions in the risk of death 
from esophageal and gastric cancer of around 50%,8 and reductions in the risk of 
metastases after non-colorectal gastrointestinal cancer diagnosis by around 60%.9 It is 
possible to speculate why we did not observe these protective effects: Firstly, the risk 
of death from cancer will reflect cancer incidence and it is plausible that aspirin could 
reduce esophageal and gastric cancer incidence but not improve survival. Similarly, as 
these trials were of aspirin treatment to reduce vascular events they were not specific 
to cancer patients and therefore all included individuals in the aspirin group were 
taking aspirin for many years prior to cancer diagnosis.  Finally, patients in these 
trials may have taken aspirin more regularly than patients in a real life setting,31;32 but 
it is worth noting that our analyses of consistent aspirin use and long term aspirin use 
were also null. 
 
At least one trial is ongoing investigating the effect of aspirin (both 100mg and 
300mg) on survival in esophageal and gastric cancer patients.14 This UK trial will 
provide more definitive evidence of the effect of low-dose aspirin in esophageal and 
gastric cancer patients, but a final report is not anticipated until 2027. Should further 
epidemiological studies observe null results in esophageal cancer patients this could 
inform the decision to conduct further trials and inform the interim analyses of this 
trial. 
 
Strengths 
The main strength of our study was the use of two large independent population-based 
cohorts, the long term follow-up (of up to 17 years), size (including 8,487 gastro-
esophageal patients making this larger than all previous studies of aspirin on survival) 
and the ability to identify cancer-specific mortality which was not possible in 
previous studies investigating post-diagnostic aspirin use. We utilised high quality 
data from a number of sources (including English and Scottish cancer registries, and 
medication and national mortality records). Also, the use of routinely electronically 
updated databases eliminated the possibility of recall bias, a significant disadvantage 
of questionnaire-based studies.33  
 
Limitations 
We cannot exclude the effect of residual confounding from poorly measured or 
missing factors. In particular, stage was poorly recorded, although this is likely to bias 
our estimates toward a more protective effect as aspirin is less likely to be prescribed 
to patients with more advanced cancer (as seen in the Netherlands cohort in which 9% 
of stage four patients used aspirin compared with 24% of stage one patients).12 
Furthermore, our conclusions were unchanged in complete case and multiple 
imputation analyses adjusting for stage in the English cohort. We had limited 
information on smoking and BMI and only from the English cohort. Despite this, 
adjustments using complete case and imputation for esophageal and gastric cancer did 
not alter results. Additionally, misclassification of aspirin is possible as aspirin is 
available over-the-counter. However, a previous CPRD study estimated that 70% to 
80% of aspirin use among middle-aged UK residents was prescription based,34 whilst 
another showed little evidence of misclassification of aspirin usage by prescription 
records when compared with patient recall.35 Also, a previous methodological study 
demonstrated that that valid treatment effects can be obtained where over-the-counter 
usage occurs particularly when medication use is around 35% and OTC use is under 
30%, as seems likely in our study.36 However, we cannot rule out the possibility of 
non-compliance. Furthermore, in other cancer sites, such as colorectal, aspirin has 
been shown to be protective only in particular molecular subtypes.37 Molecular 
subtypes have only recently been identified for esophageal adenocarcinoma,38 and as 
their association with prognosis is unknown it is too preliminary to investigate if 
stratified approaches by subtype are required. This may be, however, a component of 
future research. 
 
 
Conclusions 
In conclusion, we found there was no significant reduction in mortality in esophageal 
or gastric cancer patients with low-dose aspirin use. Our findings do not support the 
conduct of further trials of low-dose aspirin in esophageal or gastric cancer patients. 
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Table 1. Characteristics of low-dose aspirin users and non-users after esophageal cancer diagnosis, restricted 
to participants living minimum 6 months after diagnosis. 
 
 English cohort Scottish cohort 
 
Aspirin non-
user 
(2,174) 
Aspirin user 
(559) 
Aspirin non-
user 
(1,436) 
Aspirin user 
(485) 
     
Male 1,430 (65.8%) 412 (73.7%) 928 (64.6%) 343 (70.7%) 
     
Year: 1998-2002 476 (21.9%) 97 (17.4%)   
          2003-2007 721 (33.2%) 200 (35.8%)   
          2008-2012 977 (44.9%) 262 (46.9%) 1,436 (100%) 485 (100%) 
     
Age: mean (SD) 67.9 (11.8) 72.7 (9.8) 67.2 (11.4) 72.4 (9.0) 
         <59 528 (24.3%) 45 (8.1%) 356 (24.8%) 38 (7.8%) 
         60-69 659 (30.3%) 165 (29.5%) 463 (32.2%) 138 (28.5%) 
         70-79 606 (27.9%) 200 (35.8%) 398 (27.7%) 200 (41.2%) 
         80+ 381 (17.5%) 149 (26.7%) 219 (15.3%) 109 (22.5%) 
     
Grade: 1 87 (4.0%) 24 (4.3%) 30 (2.1%) 7 (1.4%) 
            2 725 (33.3%) 190 (34.0%) 454 (31.6%) 177 (36.5%) 
            3-4 817 (37.6%) 198 (35.4%) 686 (47.8%) 197 (40.6%) 
            Missing 545 (25.1%) 147 (26.3%) 266 (18.5%) 104 (21.4%) 
     
Histology: Adenocarcinoma 1,256 (57.8%) 349 (62.4%) 882 (61.4%) 296 (61.0%) 
                  Squamous 678 (31.2%) 152 (27.2%) 502 (35.0%) 165 (34.0%) 
                  Other/unknown 240 (11.0%) 58 (10.4%) 52 (3.6%) 24 (4.9%) 
     
Treatmenta,b: Surgery 879 (40.4%) 215 (38.5%) 266 (18.5%) 90 (18.6%) 
                   Chemotherapy 1,087 (50.0%) 235 (42.0%) 883 (61.5%) 256 (52.8%) 
                   Radiotherapy 550 (25.3%) 158 (28.3%) 424 (29.5%) 188 (38.8%) 
     
Deprivation: 1 (Least Deprived) 455 (20.9%) 116 (20.8%) 252 (17.5%) 66 (13.6%) 
                     2 554 (25.5%) 141 (25.2%) 274 (19.1%) 94 (19.4%) 
                     3 435 (20.0%) 110 (19.7%) 303 (21.1%) 99 (20.4%) 
                     4 412 (19.0%) 109 (19.5%) 286 (19.9%) 105 (21.6%) 
                     5 (Most Deprived) 317 (14.6%) 83 (14.8%) 321 (22.4%) 121 (24.9%) 
     
Comorbidityc     
  Chronic pulmonary disease 255 (11.7%) 77 (13.8%) 111 (7.7%) 78 (16.1%) 
  Diabetes 210 (9.7%) 114 (20.4%) 67 (4.7%) 66 (13.6%) 
  Renal disease 153 (7.0%) 71 (12.7%) 25 (5.2%) 27 (1.9%) 
  Cerebrovascular disease 72 (3.3%) 62 (11.1%) 57 (4.0%) 42 (8.7%) 
  Peripheral vascular disease 56 (2.6%) 55 (9.8%) 38 (2.6%) 29 (6.0%) 
  Myocardial infarction 28 (1.3%) 62 (11.1%) 40 (2.8%) 62 (12.8%) 
  Congestive heart disease 64 (2.9%) 31 (5.5%) 41 (2.9%) 44 (9.1%) 
  Peptic ulcer disease 47 (2.2%) 8 (1.4%) 57 (4.0%) 22 (4.5%) 
     
Statin use (after diagnosis) 345 (15.9%) 350 (62.6%) 288 (20.1%) 363 (74.8%) 
     
Staged: 1 34 (1.6%) 10 (1.8%)   
            2 69 (3.2%) 28 (5.0%)   
            3 183 (8.4%) 47 (8.4%)   
            4 132 (6.1%) 23 (4.1%)   
            Missing 1,756 (80.8%) 451 (80.7%)   
     
Smokingd: Current  542 (24.9%) 99 (17.7%)   
                  Ex 654 (30.1%) 250 (44.7%)   
                  Non-smoker 787 (36.2%) 179 (32.0%)   
                  Missing 191 (8.8%) 31 (5.6%)   
     
BMId: mean (SD) 26.5 (5.1) 27.6 (5.7)   
aIn first 6 months 
bPatients may have had more than one type of treatment 
cBefore diagnosis 
dData not reported for Scotland cohort 
 
Table 2. Characteristics of low-dose aspirin users and non-users after gastric cancer diagnosis, restricted to 
participants living minimum 6 months after diagnosis. 
 
 English cohort Scottish cohort 
 
Aspirin non-
user 
(1,895) 
Aspirin user 
(496) 
Aspirin non-
user 
(1,130) 
Aspirin user 
(312) 
     
Male 1,249 (65.9%) 368 (74.2%) 696 (61.6%) 226 (72.4%) 
     
Year: 1998-2002 516 (27.2%) 112 (22.6%)   
          2003-2007 669 (35.3%) 181 (36.5%)   
          2008-2012 710 (37.5%) 203 (40.9%) 1,130 (100%) 312 (100%) 
     
Age: mean (SD) 69.6 (12.4) 73.9 (9.1) 69.1 (12.4) 72.3 (9.2%) 
         <60 382 (20.1%) 33 (6.6%) 243 (21.5%) 24 (7.7%) 
         60-69 452 (23.9%) 112 (22.6%) 727 (28.3%) 218 (27.4%) 
         70-79 637 (33.6%) 218 (44.0%) 785 (30.6%) 341 (42.8%) 
         80+ 424 (22.4%) 133 (26.8%) 455 (17.7%) 176 (22.1%) 
     
Grade: 1 65 (3.4%) 22 (4.4%) 43 (3.8%) 9 (2.9%) 
            2 448 (23.6%) 144 (29.0%) 233 (20.6%) 81 (26.0%) 
            3-4 874 (46.1%) 177 (35.7%) 603 (53.4%) 158 (50.6%) 
            Missing 508 (26.8) 153 (30.8%) 251 (22.2%) 64 (20.5%) 
     
Histology: Adenocarcinoma 1,516 (80.0%) 419 (84.5%) 1005 (88.9%) 290 (92.9%) 
                  Squamous 18 (1.0%) 1 (0.2%) 14 (1.2%) 0 (0.0%) 
                  Other/unknown 360 (19.0%) 76 (15.3%) 111 (9.8%) 22 (7.1%) 
     
Treatmenta,b: Surgery 947 (50.0%) 273 (55.0%) 376 (33.3%) 124 (39.7%) 
                   Chemotherapy 720 (38.0%) 146 (29.4%) 587 (51.9%) 145 (46.5%) 
                   Radiotherapy 123 (6.5%) 38 (7.7%) 68 (6.0%) 13 (4.2%) 
     
Deprivation: 1 (Least Deprived) 361 (19.1%) 91 (18.4%) 206 (18.2%) 38 (12.2%) 
                     2 465 (24.6%) 112 (22.6%) 218 (19.3%) 47 (15.1%) 
                     3 376 (19.9%) 101 (20.4%) 208 (18.4%) 67 (21.5%) 
                     4 400 (21.1%) 112 (22.6%) 273 (24.2%) 83 (26.6%) 
                     5 (Most Deprived) 291 (15.4%) 79 (16.0%) 225 (19.9%) 77 (24.7%) 
     
Comorbidityc     
  Chronic pulmonary disease 225 (11.9%) 72 (14.5%) 97 (8.6%) 35 (11.2%) 
  Diabetes 202 (10.7%) 110 (22.2%) 91 (8.1%) 55 (17.6%) 
  Renal disease 126 (6.6%) 62 (12.5%) 25 (2.2%) 14 (4.5%) 
  Cerebrovascular disease 75 (4.0%) 51 (10.3%) 53 (4.7%) 45 (14.4%) 
  Peripheral vascular disease 81 (4.3%) 51 (10.3%) 34 (3.0%) 28 (9.0%) 
  Myocardial infarction 60 (3.2%) 48 (9.7%) 47 (4.2%) 46 (14.7%) 
  Congestive heart disease 72 (3.8%) 31 (6.3%) 24 (2.1%) 25 (8.0%) 
  Peptic ulcer disease 146 (7.7%) 48 (9.7%) 139 (12.3%) 31 (9.9%) 
     
Statin use (after diagnosis) 346 (18.3%) 306 (61.7%) 303 (26.8%) 233 (74.7%) 
     
Staged: 1 28 (1.5%) 12 (2.4%)   
            2 43 (2.3%) 20 (4.0%)   
            3 59 (3.1%) 16 (3.2%)   
            4 119 (6.3%) 16 (3.2%)   
            Missing 1,646 (86.9%) 432 (87.1%)   
     
Smokingd: Current  367 (19.4%) 91 (18.3%)   
                  Ex 610 (32.2%) 205 (41.3%)   
                  Non-smoker 722 (38.1%) 174 (35.1%)   
                  Missing 196 (10.3%) 26 (5.2%)   
     
BMId: mean (SD) 26.4 (4.9) 26.7 (4.6)   
aIn first 6 months 
bPatients may have had more than one type of treatment 
cBefore diagnosis 
dData not reported for Scotland cohort 
 
 
Table 3: Association between low-dose aspirin use and esophageal and gastric cancer death 
 English cohort  Scottish cohort   Pooled  
Patients Person years 
Cancer- 
deaths 
Unadjusted HR 
(95% CI) 
Adjusted HRa 
(95% CI) Patients 
Person 
years 
Cancer- 
deaths 
Unadjusted HR 
(95% CI) 
Adjusted HRa 
(95% CI) 
Adjusted HRb 
(95%CI) 
Test for 
trend p-
valuec 
Esophageal             
  Non-user 2,174 3,821 1,527 1.00 (Ref.) 1.00 (Ref.) 1,436 1,920 1,054 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)  
  User 559 1,016 340 1.05 (0.93,1.18) 1.01 (0.88,1.17) 485 631 319 1.00 (0.88,1.14) 0.95 (0.82,1.10) 0.98 (0.89,1.09)  
               < 365 tablets 386 571 271 1.06 (0.93,1.21) 1.04 (0.90,1.20) 316 412 247 0.96 (0.83,1.10) 0.91 (0.77,1.07) 0.98 (0.88,1.09) 0.88 
  ≥ 365 tablets 173 446 69 1.00 (0.78,1.28) 0.92 (0.70,1.20) 169 219 72 1.21 (0.94,1.57) 1.15 (0.88,1.50) 1.03 (0.85,1.25)  
               1-182 tablets 284 409 206 1.07 (0.93,1.24) 1.05 (0.90,1.23) 239 277 193 1.02 (0.88,1.20) 0.97 (0.82,1.16) 1.01 (0.90,1.14)  
  183-364 tablets 102 162 65 1.03 (0.80,1.33) 0.99 (0.76,1.29) 77 135 54 0.77 (0.58,1.02) 0.73 (0.54,0.98) 0.87 (0.71,1.06)  
  365-547 tablets 36 94 20 0.74 (0.48,1.16) 0.72 (0.46,1.13) 40 77 33 1.12 (0.78,1.60) 1.06 (0.73,1.53) 0.91 (0.68,1.21) 0.97 
  548-729 tablets 43 78 22 1.26 (0.82,1.94) 1.15 (0.74,1.79) 57 73 20 1.00 (0.63,1.59) 0.94 (0.59,1.49) 1.05 (0.76,1.44)  
  ≥ 730 tablets 94 273 27 1.11 (0.74,1.65) 0.97 (0.64,1.46) 72 69 19 1.89 (1.15,3.10) 1.80 (1.09,2.97) 1.25 (0.91,1.71)  
            
Esophageal adenocarcinoma            
  Non-user 1,256 2,326 881 1.00 (Ref.) 1.00 (Ref.) 882 1,211 644 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)  
  User 349 661 216 1.06 (0.92,1.24) 1.10 (0.92,1.31) 296 397 194 1.00 (0.85,1.17) 1.00 (0.83,1.21) 1.05 (0.93,1.19)  
           
Esophageal squamous cell carcinoma           
  Non-user 678 1,084 474 1.00 (Ref.) 1.00 (Ref.) 502 645 375 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)  
  User 152 256 92 1.05 (0.84,1.32) 0.90 (0.70,1.17) 165 201 110 1.03 (0.83,1.27) 0.88 (0.68,1.14) 0.89 (0.74,1.07)  
             
Gastric             
  Non-user 1,895 4,069 1,244 1.00 (Ref.) 1.00 (Ref.) 1,130 1,829 736 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)  
  User 496 1,121 234 0.93 (0.80,1.07) 0.95 (0.82,1.11) 312 493 178 1.00 (0.84,1.18) 0.97 (0.80,1.17) 0.96 (0.85,1.08)  
             
  < 365 tablets 300 595 179 0.92 (0.79,1.08) 0.94 (0.79,1.11) 199 324 138 0.96 (0.80,1.16) 0.93 (0.76,1.14) 0.94 (0.82,1.07) 0.82 
  ≥ 365 tablets 196 526 55 0.94 (0.71,1.24) 1.01 (0.76,1.35) 113 169 40 1.13 (0.81,1.58) 1.13 (0.80,1.59) 1.06 (0.85,1.32)  
             
  1-182 tablets 226 432 139 0.96 (0.80,1.14) 0.98 (0.81,1.18) 139 223 91 0.88 (0.71,1.10) 0.85 (0.67,1.08) 0.93 (0.80, 1.08)  
  183-364 tablets 74 163 40 0.82 (0.60,1.13) 0.82 (0.59,1.14) 60 101 47 1.18 (0.87,1.60) 1.16 (0.84,1.59) 0.98 (0.78, 1.23)  
  365-547 tablets 45 102 18 0.78 (0.49,1.26) 0.81 (0.50,1.30) 26 61 15 0.89 (0.53,1.50) 0.87 (0.51,1.47) 0.84 (0.59, 1.19) 0.76 
  548-729 tablets 48 88 17 1.21 (0.74,1.97) 1.36 (0.83,2.23) 29 47 14 1.46 (0.84,2.52) 1.51 (0.87,2.63) 1.43 (0.99, 2.06)  
  ≥ 730 tablets 103 336 20 0.92 (0.58,1.47) 1.03 (0.64,1.65) 58 62 11 1.30 (0.70,2.42) 1.30 (0.69,2.44) 1.12 (0.77. 1.64)  
             
Gastric adenocarcinoma            
  Non-user 1,516 3,161 1,022 1.00 (Ref.) 1.00 (Ref.) 1,005 1,565 685 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)  
  User 419 934 202 0.89 (0.77,1.04) 0.92 (0.78,1.09) 290 447 168 0.94 (0.79,1.12) 0.92 (0.76,1.12) 0.92 (0.81,1.04)  
aModel contains sex, age, year of diagnosis, deprivation, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial 
infarction, congestive heart disease, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and other prescription 
medication use (aspirin and statin use, as time varying covariates) 
bPooled results of both English and Scottish cohorts. 
cTest for trend per category increase pooled across the English and Scottish cohorts.
Table 4. Sensitivity analyses of association between aspirin use and cancer-specific and all-cause mortality for both cohorts.  
 English cohort  Scottish cohort  Pooled 
Cancer-
specific 
deaths 
Person 
years 
Unadjusted HR 
(95% CI) 
Adjusted HRa 
(95% CI) 
 Cancer-
specific 
deaths 
Person 
years 
Unadjusted HR 
(95% CI) 
Adjusted HRb 
(95% CI) 
Adjusted HRc 
(95%CI) 
Esophageal           
Main analysis (ever use)b 1,867 4,837 1.05 (0.93,1.18) 1.01 (0.88,1.17)  1,373 2,551 1.00 (0.88,1.14) 0.95 (0.82,1.10) 0.98 (0.89,1.09) 
No exposure lag  3,581 6,629 0.96 (0.88,1.05) 0.83 (0.75,0.91)  2,385 3,765 0.89 (0.81,0.98) 0.92 (0.82,1.02) 0.87 (0.81, 0.93) 
Exposure lag of 3 months 2,538 5,608 0.98 (0.89, 1.09) 0.90 (0.80, 1.01)  1,794 3,087 0.99 (0.89, 1.11) 0.98 (0.87, 1.12) 0.94 (0.86, 1.02) 
Exposure lag of 1 year 1,001 3,744 0.96 (0.82,1.14) 0.90 (0.74,1.09)  697 1,784 1.07 (0.89,1.27) 1.06 (0.86,1.30) 0.97 (0.84,1.12) 
Simplified first 6 month analysisc 1,867 4,837 1.02 (0.90,1.15) 0.98 (0.86,1.13)  1,373 2,551 0.95 (0.84, 1.08) 0.92 (0.79,1.06) 0.95 (0.86,1.05) 
Restricted to non-aspirin user priord 1,425 3,890 0.89 (0.67,1.18) 0.85 (0.64,1.14)  725 1,314 1.20 (0.87,1.67) 1.02 (0.72,1.45) 0.92 (0.73,1.14) 
Restricted to aspirin user priore 442 947 1.07 (0.87,1.32) 1.19 (0.95,1.49)  291 488 0.80 (0.61,1.04) 0.76 (0.57,1.02) 1.01 (0.84,1.20) 
Adjusting for aspirin in year priorf 1,867 4,837 1.05 (0.93,1.18) 1.03 (0.88,1.22)  1,016 1,802 1.01 (0.87,1.17) 0.89 (0.72,1.11) 0.98 (0.86, 1.11) 
In patients undergoing surgeryg 657 2,733 0.95 (0.77,1.17) 0.81 (0.63,1.03)  151 821 0.99 (0.67,1.47) 1.01 (0.61,1.67) 0.85 (0.68,1.05) 
In statin usersh 398 1,401 1.04 (0.85,1.27) 0.98 (0.79,1.21)  425 874 0.98 (0.81, 1.18) 0.99 (0.81, 1.20) 0.99 (0.85, 1.14) 
In statin non-usersi 1,469 3,436 1.31 (1.10,1.56) 1.07 (0.89,1.28)  948 1,677 1.09 (0.88, 1.36) 0.89 (0.70, 1.13) 1.00 (0.87, 1.16) 
Consistent aspirin users v non-usersj 1,867  0.95 (0.79,1.15) 0.96 (0.78,1.18)  1,350  0.89 (0.73, 1.08) 0.89 (0.68, 1.04) 0.92 (0.79,1.06) 
All-cause mortalityk 2,051 4,837 1.13 (1.01,1.26) 1.06 (0.93,1.21)  1,502 2,551 1.09 (0.96,1.22) 1.00 (0.87,1.15) 1.03 (0.93,1.13) 
Aspirin use priorl 3,581 6,629 1.11 (1.03,1.20) 0.94 (0.86,1.03)  1,798 2,720 1.13 (1.02,1.25) 0.95 (0.85,1.08) 0.94 (0.88,1.01) 
Adjusting for gradem 1,411 3,466 1.07 (0.93,1.22) 1.07 (0.91,1.25)  1,117 2,063 1.02 (0.89,1.18) 0.94 (0.80,1.11) 1.01 (0.90,1.13) 
Adjusting for stage and graden§ 281 615 0.96 (0.71,1.29) 0.88 (0.61,1.27)       
Adjusting for stage and grade (MI)o§ 1,867 4,837 1.05 (0.93,1.18) 1.00 (0.85,1.17)       
Adjusting for smoking & obesityp§ 1,444 3,864 1.08 (0.95,1.23) 1.06 (0.91,1.24)       
Adjusting for smoking & obesity (MI)q§ 1,867 4,837 1.05 (0.93,1.18) 1.02 (0.89,1.17)       
Gastric           
Main analysis (ever use)b 1,478 5,190 0.93 (0.80,1.07) 0.95 (0.82,1.11)  914 2,322 1.00 (0.84,1.18) 0.97 (0.80,1.17) 0.96 (0.84,1.07) 
No exposure lag  3,213 6,758 0.84 (0.76,0.94) 0.79 (0.71,0.88)  1,902 3,264 0.88 (0.77,0.99) 0.93 (0.82,1.07) 0.84 (0.78, 0.92) 
Exposure lag of 3 months 2,024 5,854 0.90 (0.80, 1.02) 0.88 (0.78, 1.01)  1,241 2,725 0.98 (0.85, 1.13) 1.00 (0.85, 1.17) 0.93 (0.84, 1.02) 
Exposure lag of 1 year 815 4,200 0.89 (0.73,1.07) 0.88 (0.72,1.09)  527 1,717 1.13 (0.92,1.40) 1.02 (0.80,1.31) 0.94 (0.80,1.10) 
Simplified first 6 month analysisc 1,478 5,190 0.91 (0.79,1.05) 0.94 (0.81,1.09)  914 2,322 0.96 (0.82,1.13) 0.98 (0.82,1.18) 0.96 (0.85,1.07) 
Restricted to non-aspirin user priord 1,093 3,931 1.06 (0.80,1.40) 1.01 (0.76,1.36)  456 1,122 1.19 (0.79,1.80) 1.04 (0.68,1.60) 1.02 (0.80,1.30) 
Restricted to aspirin user priore 385 1,259 0.79 (0.64,0.97) 0.84 (0.68,1.05)  205 464 0.92 (0.70,1.23) 0.96 (0.71,1.30) 0.88 (0.74,1.05) 
Adjusting for aspirin in year priorf 1,478 5,190 0.93 (0.80,1.07) 0.94 (0.79,1.11)  661 1,586 1.03 (0.85,1.25) 0.98 (0.77,1.24) 0.95 (0.83 1.10) 
In patients undergoing surgeryg 647 3,611 0.89 (0.72,1.10) 0.94 (0.74,1.20)  214 1,122 1.26 (0.92,1.72) 1.15 (0.80,1.65) 1.00 (0.82,1.22) 
In statin usersh 313 1,456 0.95 (0.75,1.19) 0.93 (0.74,1.18)  301 865 0.96 (0.76, 1.20) 0.88 (0.69, 1.11) 0.91 (0.77, 1.07) 
In statin non-usersi 1,165 3,735 1.05 (0.85,1.29) 0.95 (0.77,1.17)  613 1,457 1.23 (0.92, 1.63) 1.16 (0.86, 1.55) 1.02 (0.86, 1.21) 
Consistent aspirin users v non-usersj 1,478  0.85 (0.67,1.08) 0.97 (0.75,1.25)  896  0.90 (0.70, 1.16) 0.90 (0.72, 1.25) 0.94 (0.78,1.13) 
All-cause mortalityk 1,768 5,190 1.04 (0.92,1.18) 1.00 (0.88,1.15)  1,008 2,322 1.08 (0.92,1.26) 1.02 (0.86,1.22) 1.01 (0.90,1.12) 
Aspirin use priorl 3,213 6,758 1.02 (0.94,1.10) 0.95 (0.87,1.04)  1,399 2,283 1.05 (0.94,1.18) 0.94 (0.83,1.07) 0.95 (0.88,1.02) 
Adjusting for gradem 1,086 3,745 0.89 (0.76,1.06) 0.99 (0.82,1.19)  738 1,759 0.99 (0.82,1.19) 1.00 (0.81,1.23) 0.99 (0.86,1.13) 
Adjusting for stage and graden§ 141 388 1.00 (0.63,1.58) 1.25 (0.71,2.20)       
Adjusting for stage and grade (MI)o§ 1,478 5,190 0.93 (0.80,1.07) 0.98 (0.83,1.15)       
Adjusting for smoking & obesityp§ 1,141 4,038 0.89 (0.76,1.03) 0.89 (0.75,1.05)       
Adjusting for smoking & obesity (MI)q§ 1,478 5,190 0.93 (0.80,1.07) 0.95 (0.81,1.11)       
aExcept where otherwise stated model contains sex, age, year of diagnosis, deprivation, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to 
diagnosis, including acute myocardial infarction, congestive heart disease, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal 
disease) and other prescription medication use (aspirin and statin use, as time varying covariates). 
bAnalysis undertaken applying a lag of 6 months. 
cAnalysis comparing aspirin users in the 6 months after diagnosis to aspirin non-users in the 6 months after diagnosis. 
dAnalysis of aspirin users after diagnosis compared with aspirin non-users after diagnosis restricted to aspirin non-users in the year prior to diagnosis, restricted to diagnoses after 2009 in 
Scotland as a full year of prescriptions records not available prior to this time. 
eAnalysis of aspirin users after diagnosis compared with aspirin non-users after diagnosis restricted to aspirin users in the year prior to diagnosis, restricted to diagnoses after 2009 in Scotland 
as a full year of prescriptions records not available prior to this time. 
fAnalysis of aspirin users after diagnosis compared with aspirin non-users after diagnosis adjusting for aspirin use in the year prior to diagnosis, restricted to diagnoses after 2009 in Scotland as 
a full year of prescriptions records not available prior to this time. 
gRestricted to  patients undergoing surgery. 
hAnalysis of aspirin users after diagnosis compared with aspirin non-users after diagnosis restricted to statin users after diagnosis. 
iAnalysis of aspirin users after diagnosis compared with aspirin non-users after diagnosis restricted to statin non-users after diagnosis. 
jCase-control analysis comparing consistent aspirin users to non-users, accounting for age, gender and year in the matched design and adjusting for treatment, deprivation, comorbidities and 
statin use. In Scotland and England, 11% (144/1,350) and 8.4% (156/1,867) of cancer-specific deaths and 12% (781/6443) and 8.7% (675/7,769) of controls were consistent aspirin users in 
esophageal cancer patients. Similarly, 9% (82/896) and 6.4% (94/1,478) of cancer-specific deaths and 10% (433/4266) and 7.5% (461/6,164) of controls were consistent aspirin users in gastric 
cancer patients.     
kAnalysis of all-cause mortality.  
lAspirin users compared with non–users in year prior to diagnosis, restricted to diagnoses after 2009 in Scotland as a full year of prescriptions records not available prior to this time. 
mAdjusting for grade using complete case analysis. 
nAdjusting for stage and grade using complete case analysis. 
oAdjusting for stage and grade using multiple imputation analysis. 
pAdjusting for smoking history and obesity using complete case analysis, not conducted in Scottish cohort as stage and lifestyle data not available. 
qAdjusting for smoking history and obesity using multiple imputation analysis, not conducted in Scottish cohort as stage and lifestyle data not available. 
§Data not available for Scotland cohort. 
 
 
 
 
Figure legend 
 
Figure 1: Study flow diagram for the England and Scotland datasets showing the eligibility process for esophageal and gastric cancer patients 
 
Supplementary Figure 1: Figure illustrating the study design for the  
